Delivery Order SPE2DR25D9331-SPE2DR26FQQD2
- Not listed
- The Defense Logistics Agency (DLA) awarded a $49,531.40 firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the delivery of 4,561,926,430 units of the oncology medication Oncaspar in 5 mL vials. This contract is not associated with a set-aside designation. DMS Pharmaceutical Group holds a larger $499,999,999 single-award Indefinite Delivery Contract (IDC) with the...
- The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract worth $49,531.40 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the delivery of 3,750 units of the prescription drug Oncaspar (asparaginase pegylated) in 5 mL vials. This contract is issued under a larger single-award Indefinite Delivery Contract (IDC) valued at $499,999,999, which enables the DLA to place delivery...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, has been awarded a delivery order valued at $27.4K by the Defense Logistics Agency's Medical Supply Chain for 3,750 units of Oncaspar 5 milliliter vials. The contract is firm fixed-price with no set-aside designation and an ultimate completion date of July 28, 2025. This delivery order is issued under DMS Pharmaceutical Group's larger single-award Indefinite Delivery Contract with...
- The Defense Logistics Agency awarded a delivery order valued at $40.7K to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for 3,750 units of Asparlas (5 mL vials). This delivery order was issued under a firm fixed-price contract structure with an ultimate completion date of December 31, 2025, and represents no set-aside designation, indicating the vendor competed on an unrestricted basis. DMS Pharmaceutical Group was selected...
- The Defense Logistics Agency (DLA) awarded a $4,880.68 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois. This delivery order, issued on November 26, 2025, represents one of multiple orders placed under DMS Pharmaceutical Group's recently awarded Indefinite Delivery Contract (IDC) with the DLA under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative....
- The Defense Logistics Agency (DLA) awarded a $42,751.27 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois. This delivery order, issued on December 26, 2025, with an ultimate completion date of December 30, 2025, carries no set-aside designation and represents one of numerous purchase orders DMS has fulfilled through its primary contracting vehicle with DLA. The delivery order is...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, with a ceiling value of $43,220.28, is a firm fixed-price delivery order for the supply of 4,556,239,764 units of the oncology drug Oncaspar (pegaspargase) in 5 ml vials. The award is part of a larger indefinite delivery contract (IDC) valued at up to $499,999,999 that DMS...
- On January 13, 2026, the Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order valued at $1,524.82 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with a $499.999 billion ceiling, established on November 13, 2025, under the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN...
- The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order valued at $18,868.32 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois. This delivery order, issued on November 14, 2025, with an ultimate completion date of November 17, 2025, carries no set-aside designation and was made without a subcontracting arrangement. DMS Pharmaceutical Group is fulfilling pharmaceutical supply requirements under its...
- The Defense Logistics Agency (DLA) issued a delivery order valued at $3,243.68 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the delivery of pharmaceutical products and medical consumables. This delivery order, issued on January 12, 2026, with an ultimate completion date of February 3, 2026, was awarded on a firm fixed-price basis with no set-aside designation, indicating the contractor competed in unrestricted...
- SPE2DR25D9331Indefinite Delivery Contract
- SPE2DR25D9331-SPE2DR26FQQD2Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $40,717.98 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, on January 22, 2026. The delivery order covers 3,750 units of Oncaspar 5 milliliter vials, an oncology pharmaceutical product, with a firm fixed-price structure and an ultimate completion date of February 12, 2026. This award was issued without a set-aside designation, reflecting the contractor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group Inc. serves as the prime contractor with no identified subcontractors. This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract (IDC) with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy. The underlying IDC, awarded in November 2025 with a ceiling value of $499,999,999 and extending through December 2036, authorizes DLA to issue delivery orders for a comprehensive range of pharmaceutical products to support Department of Defense healthcare operations globally. The contractor's demonstrated performance across multiple therapeutic categories and product lines, coupled with its established position within the DLA's critical pharmaceutical supply chain, positions it to fulfill the diverse medical supply requirements of military healthcare facilities worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $40.7k | 1/21/26 |